Inotuzumab Ozogamicin Shows Similar Efficacy Among Older, Younger Patients With ALL

Share this content:
Researchers evaluated the outcomes of older vs younger patients with R/R ALL treated with InO or investigators’ choice of chemotherapy.
Researchers evaluated the outcomes of older vs younger patients with R/R ALL treated with InO or investigators’ choice of chemotherapy.

Inotuzumab ozogamicin (InO) may be an effective and tolerable first- or second-line salvage therapy option among older patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL), according to a study published in Cancer.1

Results of the INO-VATE study (ClinicalTrials.gov Identifier: NCT01564784) demonstrated that InO improves clinical outcomes among patients with ALL between 18 to 78 years old overall, but the impact of treatment on age-specific subgroups was not fully explored.

For this post-hoc analysis of INO-VATE, researchers evaluated the outcomes of older (> 55 years) vs younger patients with R/R ALL treated with InO 1.8 mg/m2/cycle or investigators' choice (IC) of chemotherapy. Baseline demographics and disease characteristics were similar between younger and older patients.

Patients treated with InO had a complete response (CR)/complete response with incomplete hematologic recovery (CRi) rate of 73% compared with 31% of patients treated with IC (1-sided P < .0001).

The CR/CRi rate was 70% and 75% among older and younger patients (1-sided P = .24), respectively. Progression-free survival, remission rates, and median durations of remission were also similar between the age-specific subgroups, but younger patients had an improved median overall survival (8.6 months vs 5.6 months, respectively).

Grade 3 or worse treatment-emergent adverse events occurred at similar frequencies in older and younger patients, but thrombocytopenia, febrile neutropenia, and γ-glutamyltransferase elevations were reported more frequently among older patients. Older patients who received InO and underwent hematopoietic stem cell transplantation had higher rates of veno-occlusive disease compared with younger patients (41% vs 17%, respectively).

The authors concluded that InO is a safe and effective treatment among older patients with R/R ALL, and added that “lower doses of InO and its combination with low-intensity chemotherapy regimens are being evaluated.”

Reference

  1. Jabbour EJ, DeAngelo DJ, Stelljes M, et al. Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE. Cancer. 2018 Jan 30. doi: 10.1002/cncr.31249/full [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs